Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysis
Version of Record online: 28 MAY 2012
Copyright © 2012 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 21, Issue 9, pages 953–963, September 2012
How to Cite
Metzke, B., Neubauer, W. C., Hieke, S., Jung, M., Wäsch, R. and Engelhardt, M. (2012), Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysis. Pharmacoepidem. Drug Safe., 21: 953–963. doi: 10.1002/pds.3278
- Issue online: 4 SEP 2012
- Version of Record online: 28 MAY 2012
- Manuscript Accepted: 13 MAR 2012
- Manuscript Revised: 1 MAR 2012
- Manuscript Received: 26 AUG 2011
- systemic antifungal drugs;
- haematology/oncology patients;
- drug interactions;
- adverse events
To assess the role of systemic antifungal drugs as well as the frequency of potential drug interactions and adverse drug events of commonly used antifungals in an unselected haematology/oncology patient cohort.
A prospective analysis was performed in our haematology/oncology department between October 2006 and September 2009. Data were obtained from 250 consecutive patients who received treatment and/or prophylaxis with fluconazole (n = 191), liposomal amphotericin B (n = 105), voriconazole (n = 62), caspofungin (n = 27) and/or posaconazole (n = 22). We performed detailed reviews of patient charts and laboratory values in close cooperation with treating physicians and nursing staff and participated regularly in ward and chart rounds. Potential drug interactions were assessed using the electronic database Micromedex® 1.0 (Healthcare Series).
In terms of adverse drug events, caspofungin (56%) and voriconazole (58%) revealed a slightly more favourable safety profile than liposomal amphotericin B (66%) and posaconazole (64%). We confirmed frequent nephrotoxic effects with the use of liposomal amphotericin B (20%). Regarding potential drug interactions, 97 (66%) of 147 evaluated patients were exposed to at least 1 of 22 different potentially interacting drug combinations involving systemic antifungal agents. Cyclosporine was the most prevalent potentially interacting drug in our cohort.
Systemic antifungal drugs are widely used in the haematology/oncology setting and exhibit numerous potential drug interactions and adverse events in cancer patients. Our results highlight the challenges related to antifungal drugs and should valuably contribute to a safe and efficient application of this increasingly important class of drugs. Copyright © 2012 John Wiley & Sons, Ltd.